2018 Cardiac Dysrhythmia Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Cardiac Dysrhythmia Market

June 2018 | 70 pages | ID: 274F13390ABEN
VPAResearch

Abstracts

Cardiac Dysrhythmia refers to abnormal rate of heart beats and effects around 6 million people in the US alone. More than 20% of these patients are hospitalized and 8-9% witness death. The pace of heart beat is irregular, or either more than the normal range (tachycardia) or slower than normal (bradycardia). Primary factors contributing to the Cardiac Dysrhythmia condition include diabetes, smoking, stress while symptoms include palpitations, short of breath etc.

To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Cardiac Dysrhythmia pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Cardiac Dysrhythmia pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Cardiac Dysrhythmia pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Contents

1 TABLE OF CONTENTS

1.1 List of LIST OF FIGURES
1.2 List of Tables

2 CARDIAC DYSRHYTHMIA PIPELINE ANALYSIS

2.1 Disease and Pipeline Overview
2.2 Cardiac Dysrhythmia Pipeline Snapshot
2.3 Cardiac Dysrhythmia Pipeline by Phase
2.4 Cardiac Dysrhythmia Pipeline by Company
2.5 Cardiac Dysrhythmia Pipeline by Mechanism of Action

3 CARDIAC DYSRHYTHMIA- COMPANY WISE PIPELINE ANALYSIS

AETAS Pharma Co.,Ltd
Armgo Pharma, Inc.
Beijing CoSci Med-Tech Co.,Ltd
Gilead Sciences, Inc.
HUYA Bioscience International, LLC
InCarda Therapeutics, Inc.
LATITUDE Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc.
Numerate, Inc.
OMEICOS Therapeutics GmbH
Ono Pharmaceutical Co., Ltd.
Sanofi SA
Servier Laboratories Limited
Sign Path Pharma Inc

4 CARDIAC DYSRHYTHMIA R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN CARDIAC DYSRHYTHMIA PIPELINE

6 APPENDIX

6.1 About VPA Research
6.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Cardiac Dysrhythmia Pipeline by Phase, H2- 2018
Figure 2: Cardiac Dysrhythmia Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Cardiac Dysrhythmia Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018

List Of Tables

LIST OF TABLES

Cardiac Dysrhythmia Pipeline by Phase, H2- 2018
Cardiac Dysrhythmia Pipeline by Companies, H2- 2018
Cardiac Dysrhythmia Pipeline by Mechanism of Action, H2- 2018
Table 1: AETAS Pharma Co.,Ltd Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
Table 2: Armgo Pharma, Inc. Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
Table 3: Beijing CoSci Med-Tech Co.,Ltd Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
Table 4: Gilead Sciences, Inc. Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
Table 5: HUYA Bioscience International, LLC Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
Table 6: InCarda Therapeutics, Inc. Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
Table 7: LATITUDE Pharmaceuticals Inc. Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
Table 8: Milestone Pharmaceuticals Inc. Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
Table 9: Numerate, Inc. Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
Table 10: OMEICOS Therapeutics GmbH Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
Table 11: Ono Pharmaceutical Co., Ltd. Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
Table 12: Sanofi SA Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
Table 13: Servier Laboratories Limited Cardiac Dysrhythmia Pipeline Drugs, H2- 2018
Table 14: Sign Path Pharma Inc Cardiac Dysrhythmia Pipeline Drugs, H2- 2018